Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545
Article
CAS
PubMed
Google Scholar
Casadei Gardini A, Carloni S, Scarpi E, Maltoni P, Dorizzi RM, Passardi A et al (2016) Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial. Oncotarget 7:10193–10202
PubMed
Google Scholar
Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012
Article
CAS
PubMed
Google Scholar
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081
Article
CAS
PubMed
Google Scholar
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
Article
ADS
CAS
PubMed
PubMed Central
Google Scholar
Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ et al (2014) Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120:1290–1314
Article
PubMed
Google Scholar
Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y et al (2012) The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett 4:324–328
CAS
PubMed
PubMed Central
Google Scholar
Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326–5334
Article
CAS
PubMed
Google Scholar
Heikkilä K, Ebrahim S, Lawlor DA (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Commun Health 61:824–833
Article
Google Scholar
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075
Article
CAS
PubMed
Google Scholar
Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K (2016) Clinical significance of the c-reactive protein to albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol 23:900–907
Article
PubMed
Google Scholar
Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K et al (2015) The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol 22:803–810
Article
PubMed
Google Scholar
Maeda K, Shibutani M, Otani H, Nagahara H, Ikeya T, Iseki Y et al (2015) Inflammation-based factors and prognosis in patients with colorectal cancer. World J Gastrointest Oncol 7:111–117
Article
PubMed
PubMed Central
Google Scholar
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444
Article
ADS
CAS
PubMed
Google Scholar
McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22:881–886
Article
PubMed
Google Scholar
Petrelli F, Barni S, Coinu A, Bertocchi P, Borgonovo K, Cabiddu M et al (2015) The Modified Glasgow prognostic score and survival in colorectal cancer: a pooled analysis of the literature. Rev Recent Clin Trials 10:135–141
Article
PubMed
Google Scholar
Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M (2013) C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One 8:e59321
Article
ADS
CAS
PubMed
PubMed Central
Google Scholar
Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y et al (2013) A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. Anticancer Res 33:3291–3294
PubMed
Google Scholar
Shibutani M, Maeda K, Nagahara H, Ohtani H, Sugano K, Ikeya T et al (2014) Elevated preoperative serum C-reactive protein levels are associated with poor survival in patients with colorectal cancer. Hepatogastroenterology 61:2236–2240
PubMed
Google Scholar
Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Yamazoe A et al (2015a) Significance of markers of systemic inflammation for predicting survival and chemotherapeutic outcomes and monitoring tumor progression in patients with unresectable metastatic colorectal cancer. Anticancer Res 35:5037–5046
PubMed
Google Scholar
Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y, Sakurai K, Hirakawa K (2015b) Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer. Surg Today 45:315–321
Article
CAS
PubMed
Google Scholar
Shibutani M, Maeda K, Nagahara H, Iseki Y, Ikeya T, Hirakawa K (2016) Prognostic significance of the preoperative ratio of C-reactive protein to albumin in patients with colorectal cancer. Anticancer Res 36:995–1001
CAS
PubMed
Google Scholar
Sugimoto K, Komiyama H, Kojima Y, Goto M, Tomiki Y, Sakamoto K (2012) Glasgow prognostic score as a prognostic factor in patients undergoing curative surgery for colorectal cancer. Dig Surg 29:503–539
Article
PubMed
Google Scholar
Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237
Article
CAS
PubMed
Google Scholar
Xu XL, Yu HQ, Hu W, Song Q, Mao WM (2015) A novel inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS One 10:e0138657
Article
PubMed
PubMed Central
Google Scholar
Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278–1286
Article
CAS
PubMed
Google Scholar
Zhou T, Zhan J, Hong S, Hu Z, Fang W, Qin T et al (2015) Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep 5:10481
Article
ADS
PubMed
PubMed Central
Google Scholar